CJC-1295 Dose Reference Table

Pre-calculated for 5mg vial + 2ml BAC water = 2500 mcg/ml concentration.

Dose (mcg) Inject Volume (ml) Syringe Units (100u)
100mcg 0.04 ml 4 units
200mcg 0.08 ml 8 units
300mcg 0.12 ml 12 units
400mcg 0.16 ml 16 units
500mcg 0.20 ml 20 units
1000mcg 0.40 ml 40 units

About CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), belonging to the GHRH peptide class. It was developed by ConjuChem Biotechnologies and is studied for its ability to stimulate growth hormone secretion from the anterior pituitary gland. There are two primary forms: CJC-1295 with DAC (Drug Affinity Complex) and CJC-1295 without DAC (also called Modified GRF 1-29 or Mod GRF).

CJC-1295 with DAC is notable in research for its exceptionally long half-life of 6–8 days. This extended duration results from the DAC moiety enabling the peptide to bind covalently to serum albumin in the bloodstream, protecting it from enzymatic degradation. This property allows for once-weekly or twice-weekly administration schedules in research protocols, in contrast to native GHRH which has a half-life of only a few minutes.

In preclinical research, CJC-1295 has been studied for its effects on growth hormone and IGF-1 levels, lean body mass, and adipose tissue. Researchers commonly combine it with GHRP-class peptides such as Ipamorelin, as GHRH and GHRP are understood to act synergistically through complementary receptor pathways on the pituitary gland. Standard research vials contain 5mg, typically reconstituted in 2ml bacteriostatic water for a working concentration of 2500 mcg/ml.

Frequently Asked Questions

In research settings, CJC-1295 (with DAC) is commonly studied at doses of 1000–2000mcg per week, often as a single weekly injection due to its long half-life. CJC-1295 without DAC is studied at 100–300mcg, administered more frequently.
CJC-1295 with Drug Affinity Complex (DAC) has a half-life of 6–8 days due to albumin binding. CJC-1295 without DAC (Modified GRF 1-29) has a half-life of roughly 30 minutes and requires more frequent administration.
A 5mg CJC-1295 vial is typically reconstituted with 2ml of bacteriostatic water, yielding 2500 mcg/ml. Inject BAC water slowly along the side of the vial and swirl gently — never shake.
With a 5mg vial reconstituted in 2ml BAC water (2500 mcg/ml), 300mcg equals 0.12ml — that is 12 units on a standard 100-unit (U-100) insulin syringe.
Yes. CJC-1295 (a GHRH analogue) is very commonly studied alongside GHRP peptides such as Ipamorelin or GHRP-6. The combination is researched for its synergistic effect on pituitary GH release through complementary receptor pathways.